[Viva] Fwd: aidsmap news: News from the 17th Annual Conference of the British HIV Association, 11 April 2011

[Margarite Sanchez]

This site has some links to interesting studies. I haven't read it yet but
one here is about the new medications for treating HepC.
all the best,
Margarite

---------- Forwarded message ----------
From: <aidsmapnews at nam.org.uk>
Date: Mon, Apr 11, 2011 at 4:37 AM
Subject: aidsmap news: News from the 17th Annual Conference of the British
HIV Association, 11 April 2011
To: margaritesanchez at gmail.com



   - News from the British HIV Association (BHIVA)
conference<#12f445a66c50080a_item1759762>
   - News from the International Liver Congress
(EASL)<#12f445a66c50080a_item1759755>
   - Further news from the 18th Conference on Retroviruses and Opportunistic
   Infections <#12f445a66c50080a_item1759756>
   - Other recent news <#12f445a66c50080a_item1759763>
   - About NAM <#12f445a66c50080a_item1759759>

    News from the British HIV Association (BHIVA) conference

*Brain impairment in people with HIV may not be as common as we thought*

Two studies presented at the 17th British HIV Association (BHIVA) conference
last week suggest that the proportion of people who have subtle brain
impairment due to HIV may not be as high as previously thought, and may in
fact be little higher than in the general population.

Read more >> <http://www.aidsmap.com/page/1758873/>

*Young adults who were infected at birth: the complexities of lifelong HIV
are increasingly apparent*

Although 85% of young adults who take antiretroviral therapy have an
undetectable viral load, the complexities and complications of lifelong HIV
infection are becoming increasingly apparent, researchers told the British
HIV Association conference in Bournemouth. Rates of hospital admissions,
co-morbidities and lipodystrophy are high.

Read more >> <http://www.aidsmap.com/page/1757484/>

*People diagnosed late in the UK are six times more likely to die of AIDS*

A twelve-year analysis of deaths in people with HIV in the United Kingdom
has shown that people who are diagnosed late are six times more likely to
die of AIDS than other people with HIV, Ruth Smith told the British HIV
Association conference in Bournemouth. Three quarters of AIDS deaths can be
attributed to late diagnosis (i.e. with a CD4 cell count below 350 cells/mm3
).

Read more >> <http://www.aidsmap.com/page/1756914/>

*A quarter of people who leave a sexual health clinic with ‘undiagnosed HIV’
are taking HIV treatment*

In the UK, around a quarter of people thought to have had their HIV
infection undiagnosed during a sexual health check-up have in fact been
previously diagnosed HIV-positive and are taking antiretroviral therapy.
These results, presented to the British HIV Association conference in
Bournemouth, provide the first objective evidence of a widely suspected
phenomenon.

Read more >> <http://www.aidsmap.com/page/1756413/>
 News from the International Liver Congress (EASL)

*New hepatitis C drugs pose many questions*

Even before new hepatitis C drugs come to market later this year, a vast
array of hepatitis C antivirals currently in clinical trials is opening up
new horizons for treatment of hepatitis C, in a situation strongly
reminiscent of the explosion of HIV drugs research in the mid-1990s.

Read more >> <http://www.aidsmap.com/page/1757210/>
 Further news from the 18th Conference on Retroviruses and Opportunistic
Infections

*More than twice the risk of failure for patients starting on abacavir with
low CD4s or high viral loads, compared with tenofovir*

A study published at the Conference on Retroviruses and Opportunistic
Infections (CROI) in February has found that patients starting therapy who
either have viral loads over 100,000 copies/ml, or who have a CD4 count
under 50 cells/mm3, are more than twice as likely to experience viral load
failure in the first 2.75 years of therapy if they start on abacavir/3TC (*
Kivexa*), compared with patients who start on tenofovir/FTC (*Truvada*).

Read more >> <http://www.aidsmap.com/page/1754653/>

*‘Near perfect’ adherence in early stages of Partners PrEP study*

Very high levels of adherence have been achieved in one of the ongoing
randomised controlled trials of oral pre-exposure prophylaxis (PrEP),
according to a poster presentation at CROI.

Read more >> <http://www.aidsmap.com/page/1739479/>

*Catch up on the news from CROI 2011*

You can read all our coverage of CROI 2011 online. As well as our news
reporting, which includes links to the official videos of the presentations,
you can also find all our summary bulletins from the conference, which are
in English, French, Spanish, Portuguese, Russian and Romanian.

www.aidsmap.com/CROI2011 >> <http://www.aidsmap.com/CROI2011>
 Other recent news

*Cotrimoxazole prophylaxis for HIV-positive infants aids growth, reduces
anaemia*

Use of daily cotrimoxazole in untreated HIV-infected infants significantly
improved growth and reduced anaemia, Andrew Prendergast and colleagues
reported in new findings from an observational analysis of the children
enrolled in the Children with Antibiotic Prophylaxis (CHAP) trial published
in the April 1 edition of *Clinical Infectious Diseases*.

Read more >> <http://www.aidsmap.com/page/1757255/>

*Large study shows that abacavir doesn't increase short or long-term risk of
heart attack*

Treatment with the anti-HIV drug abacavir does not increase the risk of
heart attack, US investigators report in the April 1st edition of *Clinical
Infectious Diseases*.

Read more >> <http://www.aidsmap.com/page/1750932/>

*Treatment breaks lead to fibrosis in HIV/HCV-co-infected patients*

Interrupting HIV therapy is associated with the progression of liver damage
in patients co-infected with HIV and hepatitis C, Canadian investigators
report in the online edition of *AIDS*.

Read more >> <http://www.aidsmap.com/page/1688714/>

*Steep rise in number of HIV-exposed infants in US emphasises importance of
prevention services*

Continued investment is needed if rates of mother-to-child transmission of
HIV in the US are to remain low, investigators write in the online edition
of the *Journal of Acquired Immune Deficiency Syndromes*.

Read more >> <http://www.aidsmap.com/page/1718461/>

*HIV drug prescribing in London to change from this month*

London HIV patients will start treatment with *Kivexa* (abacavir and 3TC)
rather than tenofovir and FTC for at least the next two years in a bid to
save money, the NHS in London has announced.

Read more >> <http://www.aidsmap.com/page/1753495/>

*Poor mental health and problematic alcohol use common in South Africa and
predict HIV risk behaviour*

Poor mental health, problematic alcohol consumption, substance use, and HIV
risk behaviours among South Africans are related, investigators report in
the online edition of the *Journal of Acquired Immune Deficiency Syndromes*.
The study was conducted in alcohol serving venues in poor areas close to
Cape Town.

Read more >> <http://www.aidsmap.com/page/1734452/>

*Tests needed for low levels of NNRTI resistance in patients new to
treatment*

Low levels of baseline resistance increase the risk of virological failure
for patients starting first-line antiretroviral therapy based on a
non-nucleoside reverse transcriptase inhibitor (NNRTI), US investigators
report in the April 6th edition of the *Journal of the American Medical
Association*.

Read more >> <http://www.aidsmap.com/page/1751136/>

*Low vitamin D associated with early sign of cardiovascular disease in
patients with HIV*

Low levels of vitamin D are associated with an important early-warning sign
of cardiovascular disease in patients with HIV, US investigators report in
the April 1st edition of *Clinical Infectious Diseases*.

Read more >> <http://www.aidsmap.com/page/1750226/>

*South Africans who have tested for HIV are more likely to discuss sexual
health issues*

South Africans who have ever tested for HIV are more likely than others to
have discussed HIV and sexual health issues with others, researchers report
in the April issue of *Sexually Transmitted Infections*. However those who
tested HIV-positive were no more likely than those testing HIV-negative to
do so.

Read more >> <http://www.aidsmap.com/page/1743818/>

*Atazanavir safe and effective for HIV/HCV patients with cirrhosis*

Atazanavir (*Reyataz*) is a safe and effective option for HIV-positive
patients who are co-infected with hepatitis C virus and who have liver
cirrhosis, investigators report in an online advance publication in the
journal *AIDS*.

Read more >> <http://www.aidsmap.com/page/1750296/>

*Pharmacy staff also critical for keeping ART patients in care, Mozambique
study suggests*

Pharmacy staff may be just as important as clinical staff in ensuring that
patients in sub-Saharan Africa are not lost to follow-up, according to a
large study of public sector HIV care and treatment clinics in Central
Mozambique.

Read more >> <http://www.aidsmap.com/page/1748765/>

*Breastfeeding infants with HIV may develop drug resistance from ARVs in
breast milk*

Two thirds of breastfeeding infants infected after birth, born to mothers on
antiretroviral therapy (ART), developed resistance to one or more
antiretroviral drugs according to Clement Zeh and colleagues in a secondary
analysis of the Kisumu Breastfeeding Study (KiBS) published in *PLoS
Medicine* this month.

Read more >> <http://www.aidsmap.com/page/1746067/>

*Entecavir and Truvada an option for HBV for treatment-experienced
HIV/HBV-co-infected patients*

A combination of entecavir with *Truvada* is an effective and safe option
for HIV/hepatitis B-co-infected patients whose current therapy is not
suppressing hepatitis B viral load, investigators from the north of England
report in the online edition of *AIDS*.

Read more >> <http://www.aidsmap.com/page/1721726/>

*Accelerated HBV vaccination schedule an option for HIV patients if CD4 cell
count is high*

An accelerated hepatitis B vaccination schedule could be an option for
HIV-positive patients with a high CD4 cell count, Dutch research published
in the April 1st edition of the *Journal of Infectious Diseases* suggests.

Read more >> <http://www.aidsmap.com/page/1719262/>

*Watch for malnutrition risk in children with HIV after starting ART*

One in nine HIV-infected children with advanced illness was hospitalised
with severe malnutrition within 12 weeks of starting antiretroviral and
these children had a 15-fold increased risk of dying within the first six
months compared to those children not hospitalised, Andrew Prendergast and
colleagues reported in the ARROW study published in the advance online
edition of *AIDS*.

Read more >> <http://www.aidsmap.com/page/1743688/>

*Once-daily nevirapine approved in United States*

The US Food and Drug Administration has approved a new once-daily extended
release formulation of nevirapine, known as Viramune XR.

Read more >> <http://www.aidsmap.com/page/1743350/>
    About NAM
 HIV Treatments Directory

Newly revised, the *HIV treatments directory* is available online and to
pre-order in print<http://www.aidsmap.com/resources/HIV-treatments-directory/page/1412506/>
.

The previous edition was reviewed in *The Lancet Infectious Diseases*:

*"HIV Treatments Directory is definitely much more than merely a directory.
*

*It is, in my opinion, a comprehensive manual...with a subject-by-subject,
rich, and up-to-date bibliography."*

We've made all the content available online, so you can read it and share it
with your networks.

"*Several other guidelines on HIV treatment are available online, but none
of these seem to be as comprehensive, organised, or as well structured as
NAM's HIV Treatments Directory"*

View the HIV Treatments Directory online here
>><http://www.aidsmap.com/resources/HIV-treatments-directory/page/1412506/>
 ¿Hablas español?

Did you know that many of our news reports have been translated into
Portuguese<http://www.aidsmap.com/translations/pt/Noticias-news/page/1332398/>and
Spanish <http://www.aidsmap.com/translations/es/Noticias/page/1330869/>?

Our Spanish partners, gTt, have put together a short survey (in
Spanish)<https://www.surveymonkey.com/s/actualizacion_tratamientos>to
find out about how people are using the translations of our news.

Nuestra organización colaboradora en España – gTt – ha puesto en marcha una
pequeña encuesta (en
español)<https://www.surveymonkey.com/s/actualizacion_tratamientos>para
recabar información sobre el uso de nuestras noticias en ese idioma.

Estaríamos muy agradecidos si pudierais dedicar unos minutos a completarla.

Pincha aquí para acceder a la encuesta
>><https://www.surveymonkey.com/s/actualizacion_tratamientos>
 IAS 2011 - satellite meetings: deadline 15 April

The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment
and Prevention (IAS 2011 <http://www.ias2011.org/>) will take place in Rome,
17-20 July.

Industry-sponsored satellite meetings take place in the conference centre
but are co-ordinated by the organisation hosting the satellite. The contents
and speakers of the meetings are reviewed by the programme committee to
ensure they meet the scientific and ethical principles of the conference.

A limited number of satellite meetings sponsored by non-commercial
organisations will be available. *The deadline for applications to host a
satellite is 15 April.*

Full information about satellites at IAS 2011 is available on the conference
website here <http://www.ias2011.org/Default.aspx?pageId=295>. Please
contact satellites at ias2011.org for additional information.
 Sponsor a runner

Only six days to go until the Virgin London Marathon 2011!

Our two runners, Janey and Craig, are doing an amazing job of training for
the marathon and fundraising for us.

If you'd like to support their efforts, visit www.aidsmap.com/runners or go
straight to their donation pages:

Donate to Janey
>><http://uk.virginmoneygiving.com/fundraiser-web/fundraiser/showFundraiserProfilePage.action?userUrl=JaneySewell>

Donate to Craig
>><http://uk.virginmoneygiving.com/fundraiser-web/fundraiser/showFundraiserPage.action?userUrl=CraigBurrell&pageUrl=3>

*NAM Publications*
Registered office: Lincoln House, 1 Brixton Road, London SW9 6DE
Company limited by guarantee. Registered in England & Wales, number: 2707596
Registered charity, number: 1011220

tel: +44 (0)20 7840 0050 | fax: +44 (0)20 7735 5351 | email:
info at nam.org.uk| web:
www.aidsmap.com

To unsubscribe from this email, please visit www.aidsmap.com/page/1492854/
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.resist.ca/pipermail/viva/attachments/20110428/79c897d8/attachment.html>